Blood-based Biomarker For Alzheimer’s Disease Diagnostics Market (2025 - 2033)

Blood-based Biomarker For Alzheimer’s Disease Diagnostics Market Summary

The global blood-based biomarker for Alzheimer’s disease diagnostics market size was estimated at USD 139.69 million in 2024 and is expected to reach USD 429.31 million by 2033, growing at a CAGR of 15.07% from 2025 to 2033. A pivotal catalyst was the U.S. FDA’s May 16, 2025, marketing clearance of Fujirebio’s Lumipulse G pTau217/β-amyloid 1-42 plasma ratio-the first Alzheimer’s blood test cleared to aid diagnosis-quickly followed by Labcorp’s nationwide launch on Aug 18, 2025.

These steps lower adoption friction (regulatory clarity, distribution) and are expected to accelerate payer uptake and clinician ordering, intensifying the growth curve for blood tests relative to imaging and CSF. Guidance presented at AAIC 2025 and published by the Alzheimer’s Association states that blood-based biomarker (BBM) tests with ≥90% sensitivity and ≥75-90% specificity can triage-and at higher performance, substitute for-amyloid PET or CSF testing in appropriate patients. p-tau217-containing panels consistently outperform earlier generations (Aβ42/40 or p-tau181 alone) for detecting amyloid and tau pathology. Real-world product data are converging: Quest’s 2025 AD-Detect™ reported >90% sensitivity and specificity for Alzheimer’s pathology in AAN-presented analyses, while clinical summaries highlight ~92% positive and ~97% negative agreement for the FDA-cleared Lumipulse test. As clinicians gain confidence in rule-in/rule-out accuracy, ordering shifts from specialty memory clinics to broader frontline settings, expanding test volumes and normalizing BBMs as the first diagnostic step.

Technology maturation and clinical validation add momentum. Blood assays targeting phosphorylated tau (especially p-tau217) have received Breakthrough Device designations and now full FDA clearance, reflecting strong clinical validity and utility.

Academic-industry consortia (e.g., UW-Madison, Johns Hopkins, Lund) supplied pivotal data underpinning the cleared IVD. Published reviews conclude that blood-based biomarker tests (BBMTs) bring value by reducing invasiveness and enabling earlier triage-crucial when disease-modifying therapies are most effective in prodromal/mild stages. Market traction examples include reference-lab launches and hospital adoption for memory-clinic pathways, where a positive p-tau217/Aβ ratio can expedite PET scheduling while a negative result can avoid costly scans. As platforms scale, expect menu expansion (neurofilament light, GFAP, Aβ42/40), reflex algorithms, and bundled panels, improving sensitivity/specificity and supporting longitudinal monitoring-opening recurring-test revenue beyond one-time diagnosis.

Market Concentration & Characteristics

The market demonstrates high innovation, driven by assays measuring p-tau217, Aβ42/40, and neurofilament light. Advances in multiplexing, AI-driven analytics, and early-stage detection are transforming diagnostics. FDA’s first clearance validates clinical reliability, spurring broader adoption and stimulating competitive R&D pipelines among diagnostics and biotech firms.

Mergers and acquisitions increasingly shape this market, as large diagnostics players acquire startups with proprietary biomarker technologies. Strategic deals expand assay platforms, enhance neurodegenerative disease portfolios, and accelerate commercialization. Partnerships with pharmaceutical firms for companion diagnostics are rising, aligning biomarker testing with disease-modifying therapies and reinforcing end-to-end Alzheimer’s care pathways.

Regulation is pivotal, with FDA clearance of p-tau217/Aβ42 tests marking a breakthrough for clinical adoption. CMS’s conditional coverage and state-level mandates drive payer alignment. Europe’s evolving CE-IVD frameworks support wider market entry. These developments reduce barriers, strengthen physician confidence, and promote standardized diagnostic use in both research and clinical settings.

Companies are broadening test menus beyond amyloid and tau, incorporating markers like GFAP and neurofilament light to enhance diagnostic accuracy and disease staging. Launches include multiplex blood panels, lab-developed tests, and IVD kits. Integration with digital platforms enables longitudinal monitoring, expanding biomarker utility from early detection to therapy response assessment.

North America leads adoption, propelled by FDA approvals and payer policy shifts, while Europe advances via CE-marked tests. Asia-Pacific shows the fastest projected growth, fueled by aging populations and infrastructure investments. Companies increasingly target China, Japan, and South Korea with localized strategies, clinical collaborations, and partnerships to scale access.

Type Insights

On the basis of type, tau-related markers accounted for the largest market share of over 37% in 2024. Phosphorylated tau isoforms-especially p-tau181, p-tau217, and p-tau231-have shown superior sensitivity and specificity in differentiating Alzheimer’s disease from other dementias. Among these, p-tau217 has demonstrated accuracy levels approaching 90%, making it a leading candidate for routine clinical use. In May 2025, the FDA cleared the first p-tau217/Aβ42 plasma ratio test, validating tau biomarkers as clinically reliable diagnostics and establishing a regulatory precedent. Market analysts project this segment to grow at a double-digit CAGR through 2030, driven by the clinical need for less invasive, cost-effective alternatives to PET scans and lumbar punctures. Tau-related assays are also being integrated into multiplex panels with amyloid and neurofilament markers, enhancing staging and monitoring. With ongoing payer discussions and pharma collaborations for therapy monitoring, tau biomarkers are positioned as the backbone of blood-based Alzheimer’s diagnostics.

The amyloid-related markers segment is experiencing rapid growth. While amyloid PET imaging remains the gold standard, blood-based amyloid tests are increasingly recognized as cost-effective, minimally invasive pre-screening tools. Recent FDA clearance of assays combining amyloid (Aβ42) with tau ratios underscores amyloid’s enduring diagnostic value. The segment is projected to grow steadily, supported by integration into triage strategies that prioritize patients for confirmatory imaging or lumbar puncture, reducing healthcare costs. Advances in assay sensitivity and standardization are enhancing reproducibility, enabling broader adoption in both clinical trials and early detection programs. As disease-modifying therapies such as anti-amyloid monoclonal antibodies expand, demand for blood-based amyloid testing will accelerate, positioning this segment as a critical component of Alzheimer’s patient identification and therapeutic eligibility pathways.

Technology Insights

Immunoassay held the largest market share in 2024, owing to its established use, scalability, and compatibility with clinical workflows. Techniques such as ELISA, chemiluminescent immunoassays, and fully automated immunoassay platforms are widely employed to measure key biomarkers like p-tau217, p-tau181, Aβ42/40, and GFAP with high sensitivity. FDA clearance of the first Alzheimer’s blood test in 2025, based on an automated immunoassay platform-has validated the reliability of this technology for routine diagnostic use. Market growth is fueled by rising adoption in hospital labs, reference laboratories, and pharmaceutical trials where immunoassays offer cost efficiency and throughput advantages over mass spectrometry. Analysts project this segment to expand significantly through 2030, driven by the need for early detection, therapy monitoring, and integration into treatment eligibility pathways. With continuous innovation in ultrasensitive immunoassay platforms, the segment will remain central to expanding accessibility of Alzheimer’s diagnostics worldwide.

The next-generation platforms segment in the blood-based biomarker for Alzheimer’s disease diagnostics market is anticipated to grow at the fastest rate over the forecast period. These technologies offer ultra-sensitive detection of low-abundance analytes, enabling precise quantification of p-tau isoforms, Aβ42/40 ratios, and neurofilament light. Mass spectrometry, in particular, is gaining traction as a reference method for assay validation and regulatory submissions, while Simoa has become a gold standard for research applications and early clinical use. Although currently more costly than immunoassays, next-generation platforms are projected to grow at the fastest CAGR through 2030, fueled by their role in advancing early detection and companion diagnostics for disease-modifying therapies. Pharma collaborations, academic validation studies, and automation advances are expanding adoption beyond research into specialized clinical settings. As standardization improves and costs decline, these platforms will transition from niche to mainstream, underpinning precision diagnostics in Alzheimer’s disease.

End-use Insights

Clinical laboratories & hospital labs dominated the market in 2024, as these facilities are the primary hubs for high-throughput, standardized testing. The 2025 FDA clearance of a p-tau217/Aβ42 immunoassay for symptomatic adults has accelerated adoption in hospital labs, which are now integrating these tests into dementia care pathways as triage tools before PET scans or lumbar punctures. Clinical reference labs are expanding their menu with Alzheimer’s blood tests, creating accessibility for community physicians and supporting pharmaceutical trials. This segment’s growth is fueled by increasing demand for early diagnosis, therapeutic eligibility testing, and longitudinal monitoring of disease progression. Analysts forecast strong double-digit CAGR for clinical and hospital labs through 2030, supported by automation, reimbursement shifts, and collaborative networks between academic centers and commercial labs. Together, they form the backbone for scaling Alzheimer’s disease diagnostics worldwide.

The other segment -comprising diagnostic centers, outpatient clinics, memory care centers, and direct-to-consumer (DTC) testing providers-is expected to grow at the fastest compound annual growth rate (CAGR) over the forecast period. Unlike hospital-based labs, these facilities focus on accessibility and early detection, particularly for at-risk or pre-symptomatic populations. Memory clinics are increasingly adopting blood tests as first-line screening tools, helping prioritize patients for confirmatory PET imaging or CSF analysis. Additionally, DTC companies are entering the space by offering Alzheimer’s risk panels bundled with genetic and wellness testing, appealing to health-conscious consumers. Diagnostic centers benefit from partnerships with pharma companies conducting decentralized clinical trials that require scalable biomarker testing. Although currently smaller in revenue share, this segment is projected to grow at a robust CAGR through 2030, driven by convenience, consumer awareness, and the shift toward community-based precision diagnostics outside traditional hospital settings.

Regional Insights

North America blood-based biomarker for Alzheimer’s disease diagnostics market is experiencing strong growth, due to early regulatory approvals, high healthcare spending, and widespread adoption of advanced diagnostics. The FDA’s clearance of a blood-based p-tau217/Aβ42 test in 2025 has legitimized clinical use and boosted adoption across labs. Strong pharmaceutical pipelines and ongoing clinical trials further support demand, as biomarker testing becomes critical for therapy eligibility. Growing Alzheimer’s prevalence, favorable reimbursement pathways, and integration into memory care programs add momentum.

U.S. Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market Trends

The blood-based biomarker for Alzheimer’s disease diagnostics market in the U.S. is fueled by an advanced healthcare infrastructure and the highest adoption of FDA-approved Alzheimer’s diagnostics. Rising patient demand for non-invasive testing and CMS policies linking biomarker use with anti-amyloid therapy coverage are key growth drivers. Expanding clinical lab networks, payer discussions, and academic-industry collaborations also foster rapid scale-up.

Europe Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market Trends

The Blood-based biomarker for Alzheimer’s disease diagnostics market in Europe is driven by CE-IVD approvals, pan-European research consortia, and structured dementia screening programs. Governments emphasize early detection to reduce long-term healthcare costs. Adoption is accelerating in specialized clinics and research hubs, particularly as biomarkers are integrated into clinical trial protocols. Harmonization efforts across the EU further promote consistent implementation.

The UK Blood-based biomarker for Alzheimer’s disease diagnostics market is growing rapidly. The UK market benefits from the NHS’s focus on early dementia diagnosis, combined with academic leadership in Alzheimer’s biomarker research. National dementia strategies encourage integration of innovative diagnostics. Collaborations between universities, biotech firms, and memory clinics foster adoption. Government funding and patient advocacy groups also support broader implementation and accessibility.

The blood-based biomarker for Alzheimer’s disease diagnostics market in Germany is witnessing progressive growth, supported by a strong diagnostics industry, advanced lab infrastructure, and public health emphasis on early dementia care. High adoption in hospital-based labs and memory clinics drives usage. Robust collaborations between academia, pharma, and diagnostics firms, along with CE-marked assay availability, strengthen clinical acceptance and scalability.

Asia Pacific Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market Trends

The blood-based biomarker for Alzheimer’s disease diagnostics market in Asia-Pacific is growing rapidly, fueled by rapidly aging populations, rising dementia incidence, and increasing healthcare investments. Governments in Japan, China, and South Korea are prioritizing early detection programs. Expanding lab infrastructure, growing awareness, and multinational clinical trial activity accelerate adoption. Local manufacturing and partnerships aid cost-effective test deployment.

Japan is gradually embracing Blood-based biomarkers for Alzheimer’s disease diagnostics, due to its aging society and government commitment to dementia care innovation. Strong academic research, integration of biomarkers into dementia guidelines, and widespread adoption of advanced diagnostics fuel growth. Collaborations with global firms ensure rapid technology transfer, supporting early clinical use nationwide.

The blood-based biomarker for Alzheimer’s disease diagnostics market in China is expanding rapidly, propelled by government-backed aging initiatives, rapid expansion of diagnostic labs, and rising Alzheimer’s prevalence. Domestic biotech companies are investing in amyloid and tau biomarker platforms, while global firms partner locally to enter the market. Affordability-focused innovation and large patient pools provide substantial opportunities for scaling adoption.

Latin America Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market Trends

The blood-based biomarker for Alzheimer’s disease diagnostics market in Latin America is driven by rising awareness, urbanization, and increasing dementia prevalence. Countries like Brazil and Mexico are improving their healthcare infrastructure and participating in multinational Alzheimer’s trials. Private diagnostic centers and memory clinics lead to adoption, while international partnerships help bridge technological and cost-related barriers.

MEA Blood-based Biomarker for Alzheimer’s Disease Diagnostics Market Trends

The Middle East and Africa region shows strong potential for long-term Blood-based biomarkers for Alzheimer’s disease diagnostics. Rising life expectancy and a growing elderly population are increasing the prevalence of Alzheimer’s across the region. Governments, particularly in Gulf countries like Saudi Arabia and the UAE, are investing heavily in healthcare modernization and digital health infrastructure, creating opportunities for the adoption of advanced diagnostic tools. International collaborations with European and U.S. research institutions are fostering early clinical use, while multinational diagnostic companies are entering the region through partnerships. Although limited awareness, affordability issues, and infrastructure gaps remain barriers in parts of Africa, expanding private healthcare, memory clinics, and telemedicine platforms are expected to gradually drive biomarker uptake and market expansion.

Key Blood-based Biomarker For Alzheimer’s Disease Diagnostics Company Insights

Key players operating in the blood-based biomarker for Alzheimer’s disease diagnostics market are undertaking various initiatives to strengthen their presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are key in propelling the market growth.

Recent Developments

• In May 2025, Fujirebio announced that the U.S. Food and Drug Administration (FDA) had granted 510(k) clearance for its Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test. Designed to assess amyloid pathology in individuals being evaluated for Alzheimer’s disease or other causes of cognitive decline, the test had previously received Breakthrough Device Designation from the FDA. It now becomes the first FDA-cleared blood-based IVD test in the U.S. to support the identification of patients with amyloid pathology linked to Alzheimer’s disease (AD).

• In July 2025, at the Alzheimer’s Association International Conference (AAIC) in Toronto, the Alzheimer’s Association unveiled its first clinical practice guideline (CPG) for the diagnosis, treatment, and care of Alzheimer’s disease and related dementias. This initial guideline emphasizes the use of blood-based biomarker (BBM) tests by specialists to evaluate Alzheimer’s pathology in individuals with cognitive impairment. Developed as part of the Association’s ALZPro initiative-a centralized hub for dementia professionals-the guideline provides evidence-based resources to support earlier and more accurate diagnosis, ensuring timely access to appropriate treatment.

• In May 2025, researchers at the Keck School of Medicine of USC introduced a new blood test capable of detecting early indicators of Alzheimer’s disease by measuring proteins associated with the condition. Called the Penta-Plex Alzheimer’s Disease Capture Sandwich Immunoassay (5ADCSI), the test simultaneously measures five biomarkers-more than current blood tests-and is compatible with laboratory equipment already widely in use. A proof-of-concept study, supported by the National Institutes of Health, was recently published in the Journal of Alzheimer’s Disease

• In April 2024, Labcorp, a global leader in innovative and comprehensive laboratory services, announced the nationwide rollout of its pTau-217/Beta Amyloid 42 Ratio test. This advanced blood-based biomarker assay is designed to support the diagnosis of Alzheimer’s disease and further strengthens Labcorp’s expanding portfolio of blood-based diagnostics for Alzheimer’s and other dementias.

Blood-based Biomarker For Alzheimer’s Disease Diagnostics Market